Surgery Combined With Peritonectomy Procedures and Intraperitoneal Chemohyperthermia in Abdominal Cancers With Peritoneal Carcinomatosis: A Phase II Study

Gléhen, Olivier; Mithieux, François; Osinsky, D.; Beaujard, Annie Claude; Freyer, Gilles; Guertsch, Ph.; François, Y.; Peyrat, Patrice; Panteix, G.; Vignal, J; Gilly, François-Noël

doi:10.1200/jco.2003.06.139

Cited by 231 publications

(116 citation statements)

References 22 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…The rate of the tumor cell exposure with T3 correlates with the size of the stomach serosa that is affected; this is 10 cm 2 in 17.3% of patients and 20 cm 2 in 68.5% of patients (19).…”

Section: Surgerymentioning

confidence: 99%

“…For those with resectable stage III GC, their chances of surviving more than 5 years are 4.9 times higher with HTCT than after surgery only. Indications for HTCT are an infiltrative tumor that has spread onto the serosa, disease of T3-4 stage (III or IV growth type according to the Borrmann classification), low-differentiated tumors with spread onto the serosa (T3-4), metastatic affection of the retroperitoneal (celiac) lymph nodes, and the detection of free tumor cells during intraoperative lavage (Sugarbaker P.H., 2003) (19). The given method is suitable for a large number of patients in Ukraine, and can considerably improve the results of treatment.…”

Section: Surgerymentioning

confidence: 99%

See 1 more Smart Citation

Current practice for gastric cancer treatment in Ukraine

Sydiuk

2017

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

IntroductionGastric cancer (GC) is a significant and unsolved problem, despite a slight decrease in its morbidity. Globally, 952,000 new GC cases were registered in 2012. In South Korea and Japan, because of screening for GC, the 5-year survival rate is more than 60%. In most other countries, this value is 2-3 times lower (1,2). In Ukraine, GC is a serious problem. Annually, the country registers more than 8,000 new GC cases. The disease is usually diagnosed at stage III-IV (65% of cases) and 62.2% of patients die within 1 year. About 70% of patients with GC need chemotherapy, and for most of them, this is the only way to increase their life expectancy. Morbidity and death rateAccording to the national cancer register of Ukraine, there were 8,350 new cases of GC in 2014 (5,104 in men and 3,246 in women). Thus, the morbidity rate is 23.0 cases per 100,000 people (30.3 for men and 16.7 for women), which puts the disease in fourth place for men and eighth place for women for morbidity as a result of malignant tumors in Ukraine. During the period under investigation, 6,414 patients diagnosed with GC died. The death rate was 17.7 cases per 100,000 people (23.8 for men and 12.3 for women), which means that, for men and women respectively, GC has the second and third highest death rates from malignant tumors in Ukraine.People diagnosed with GC for the first time are diagnosed at the following stages according to the TNM classification: stage I-II, 37.6%; stage III, 22.5%; stage IV, 33.9%; and indistinct stage, 5%. Thus, advanced GC is diagnosed for the first time in as many as 60% of all patients, which leads to a high death rate of more than 50% during the first year.The above information allows us to conclude that the early diagnosis of GC, as well as combined methods of treating it with neo-adjuvant and adjuvant therapy, is of paramount importance in Ukraine.Despite the gradual decline in GC morbidity, there are still some serious associated problems. Namely, in the last 10 years, the following was noted ( Table 1): (I) very few changes in the morbidity rate for women; (II) decrease in the diagnosis of stage I-II disease in spite of the necessary endoscopic equipment; (III) high death rate within 1 year.Given this information, we should define the most of patients with GC need chemotherapy, and for most of them, this is the only way to increase their lifeexpectancy. An unsolved problem of nationwide importance is achieving the early diagnosis of GC, which predetermines the treatment outcome. The 5-year survival rate for GC patients in Ukraine is only 13%, while early diagnosed GC is almost totally curable using surgery. Another important task is the development of national diagnosis and treatment standards, which will be based on national breakthroughs and will meet modern international requirements.

show abstract

“…The rate of the tumor cell exposure with T3 correlates with the size of the stomach serosa that is affected; this is 10 cm 2 in 17.3% of patients and 20 cm 2 in 68.5% of patients (19).…”

Section: Surgerymentioning

confidence: 99%

Section: Surgerymentioning

confidence: 99%

Current practice for gastric cancer treatment in Ukraine

Sydiuk

2017

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

show abstract

“…At the end of each surgical procedure after complete cytoreduction, a HIPEC infusion was carried out with the patient under general anesthesia and general hypothermia. HIPEC was performed using the closed abdomen technique at a temperature of 42°C (Glehen et al 2003), with the choice of cytotoxic agent and duration of hyperthermia depending on the site of carcinomatosis: oxaliplatin for colorectal carcinomatosis, cisplatin plus mitomycin C or mitomycin C plus irinotecan for pseudomyxoma peritonei, cisplatin for primary ovarian carcinomatosis, or mitomycin C plus cisplatin for peritoneal mesothelioma. This combined procedure enables the delivery of high concentrations of cytotoxic agents to the abdomen and provides the combined cytotoxicity of chemotherapy and heat to destroy microscopic residual tumor cells.…”

Section: Hipec Proceduresmentioning

confidence: 99%

Impact of hyperthermic intraperitoneal chemotherapy on Hsp27 protein expression in serum of patients with peritoneal carcinomatosis

Képénékian

Aloy

Magné

et al. 2013

Cell Stress and Chaperones

View full text Add to dashboard Cite

show abstract

“…Complete surgical resection, including cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC), is standard therapy for appendiceal carcinoma pseudomyxoma peritonei, and other diseases [11][12][13][14][15][16][17][18] , and multimodal therapy consisting of complete cytoreduction and HIPEC has been found to improve survival in many studies of carcinomatosis 2,[19][20][21][22][23][24][25] . Among patients with DSRCT, even after chemotherapeutic cytoreduction and surgical resection of gross, visible disease, microscopic residual disease is often present.…”

Section: Surgical Therapymentioning

confidence: 99%

Management of Desmoplastic Small Round Cell Tumor

Hayes‐Jordan¹

2017

Unusual Cases in Peritoneal Surface Malignancies

View full text Add to dashboard Cite

Desmoplastic small round cell tumor (DSRCT) is a soft tissue sarcoma of mesenchymal cell origin that typically presents with multiple intra-abdominal tumors and exhibits a multi-phenotypic pattern of immunohistochemical staining. The specific organ or tissue type of origin has yet to be identified. DSRCT rarely arises as a singular tumor in the abdomen; in most cases, there are dozens to hundreds of abdominal peritoneal tumors that are detected on diagnosis. One very large dominant mass is usually present in the omentum, with an additional one or two large conglomerates of tumors in the pelvis and right peritoneum, respectively. Despite an often overwhelmingly large number of abdominal tumors, symptoms of bowel obstruction are rare. Ascites may be present. In late stages, pleural effusions, pleural implants, mediastinal adenopathy, supraclavicular adenopathy, or bone metastasis may be present. With this challenging disease, multidisciplinary therapy, including aggressive surgery, is warranted. This review will address DSRCT biology and treatment options and discuss outcomes.

show abstract

Surgery Combined With Peritonectomy Procedures and Intraperitoneal Chemohyperthermia in Abdominal Cancers With Peritoneal Carcinomatosis: A Phase II Study

Abstract: IPCH and PP are able to achieve unexpected long-term survival in patients with bulky PC. However, one must be careful when selecting the patients for such an aggressive treatment, as morbidity rate remains high even for an experienced team.

Cited by 231 publications

References 22 publications

Current practice for gastric cancer treatment in Ukraine

Current practice for gastric cancer treatment in Ukraine

Impact of hyperthermic intraperitoneal chemotherapy on Hsp27 protein expression in serum of patients with peritoneal carcinomatosis

Management of Desmoplastic Small Round Cell Tumor

Contact Info

Product

Resources

About